Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Stembiosys Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit.
KNIGHT, TERESA E is the busiest examiner, with 1 pending matter. The current profile therefore presents one prosecution path and one technical setting for focused response planning.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KNIGHT, TERESA E | 1 | 66.1% | +48.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18947876 | AMNIOTIC FLUID CELL-DERIVED EXTRACELLULAR MATRIX AND USES THEREOF | KNIGHT, TERESA E | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947876 | AMNIOTIC FLUID CELL-DERIVED EXTRACELLULAR MATRIX AND USES THEREOF | KNIGHT, TERESA E | 1634 | DP | Non-Final OA | — | Pending | Nov 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStembiosys Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Teresa E Knight has the most, with 1 of Stembiosys Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
